OBJECTIVES: Sickle cell disease-related pain is difficult to treat adequately. Pain secondary to vasoocclusive episodes (VOE) may be unresponsive to high-dose intravenous opiates. Alternative treatment options for VOE are needed. We sought to review our experience with low-dose ketamine for children hospitalized with VOE. METHODS: Retrospective medical chart reviews were conducted for hospitalized patients treated with ketamine for sickle cell VOE. Data gathered included vital signs, pain scores, opiate utilization, and adverse events. RESULTS: Five children and adolescents received a low-dose ketamine infusion for the treatment of sickle cell-related pain. Four received the infusion in addition to opiates (delivered via patient controlled analgesia) as a rescue intervention after several days of inadequate pain relief and 1 patient received ketamine in place of opiates. Two of the 5 patients achieved what seems to be clinically significant pain control with a low-dose ketamine infusion, whereas 1 additional patient had significant reduction in opiate utilization. DISCUSSION: Further research into ketamine for vasoocclusive pain is warranted.
OBJECTIVES: Sickle cell disease-related pain is difficult to treat adequately. Pain secondary to vasoocclusive episodes (VOE) may be unresponsive to high-dose intravenous opiates. Alternative treatment options for VOE are needed. We sought to review our experience with low-dose ketamine for children hospitalized with VOE. METHODS: Retrospective medical chart reviews were conducted for hospitalized patients treated with ketamine for sickle cell VOE. Data gathered included vital signs, pain scores, opiate utilization, and adverse events. RESULTS: Five children and adolescents received a low-dose ketamine infusion for the treatment of sickle cell-related pain. Four received the infusion in addition to opiates (delivered via patient controlled analgesia) as a rescue intervention after several days of inadequate pain relief and 1 patient received ketamine in place of opiates. Two of the 5 patients achieved what seems to be clinically significant pain control with a low-dose ketamine infusion, whereas 1 additional patient had significant reduction in opiate utilization. DISCUSSION: Further research into ketamine for vasoocclusive pain is warranted.
Authors: Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang Journal: Blood Adv Date: 2020-06-23
Authors: Katie L Strong; Yao Jing; Anthony R Prosser; Stephen F Traynelis; Dennis C Liotta Journal: Expert Opin Ther Pat Date: 2014-10-29 Impact factor: 6.674
Authors: Mohammed S Alshahrani; Amal H AlSulaibikh; Mohamed R ElTahan; Sukayna Z AlFaraj; Laila P Asonto; Abdullah A AlMulhim; Murad F AlAbbad; Nisreen Almaghraby; Mohammed A AlJumaan; Thamir O AlJunaid; Moath N Darweesh; Faisal M AlHawaj; Alaa M Mahmoud; Bader K Alossaimi; Shaikhah K Alotaibi; Talal M AlMutairi; Duaa A AlSulaiman PharmD; Dunya Alfaraj; Reem Alhawwas; Lawrence Mbuagbaw; Kim Lewis; Madeleine Verhovsek; Mark Crowther; Gordon Guyatt; Waleed Alhazzani Journal: Acad Emerg Med Date: 2021-09-21 Impact factor: 5.221
Authors: Raissa Nobrega; Kathy A Sheehy; Caroline Lippold; Amy L Rice; Julia C Finkel; Zenaide M N Quezado Journal: Pediatr Res Date: 2017-09-13 Impact factor: 3.756